EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Clinical trials for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) trials appear
Sign up with your email to follow new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy cocktail takes on tough lung cancer
Disease control Recruiting nowThis study tests whether adding extra immunotherapy drugs to a standard chemo-immunotherapy combo can better treat extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups. All get ivonescimab plus …
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New hope for tough lung cancer: experimental drug faces standard care in major trial
Disease control Recruiting nowThis study tests whether the drug sacituzumab govitecan helps people with advanced small cell lung cancer live longer compared to standard treatments. About 695 adults whose cancer worsened after initial chemotherapy will receive either the study drug or usual care. The main goal…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New hope for hard-to-treat lung cancer? early trial combines experimental drug, immunotherapy, and radiation.
Disease control Recruiting nowThis early-phase trial is testing a new drug called iadademstat, taken as a liquid by mouth, together with the immunotherapy atezolizumab and targeted radiation (SBRT) in people with extensive-stage small-cell lung cancer that has persisted, come back, or gotten worse after initi…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
Triple threat: Immuno-Chemo-Radiation combo targets tough lung cancer
Disease control Recruiting nowThis Phase 2 trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer getting worse. About 56 participants who have not had prior treatment will rec…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Hope for aggressive lung cancer: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called teniposide in people with a fast-growing type of lung cancer (extensive-stage small cell lung cancer) that has a specific gene change (c-Myc-driven). The cancer must have gotten worse after standard treatments. The goal is to see if teniposide can s…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control Recruiting nowThis study tests a new treatment for people with extensive stage small cell lung cancer, a fast-growing cancer that has spread. Participants first get a drug called tislelizumab plus chemotherapy, then chest radiation if the cancer shrinks, followed by maintenance tislelizumab fo…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New hope for aggressive lung cancer: experimental drug combo enters final testing
Disease control Recruiting nowThis study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Promising drug cocktail aims to stall aggressive lung cancer
Disease control Recruiting nowThis study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive the drug combo every 21 days for up to 2 years, w…
Matched conditions: EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Phase: PHASE2 • Sponsor: Bindu R Potugari • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC